Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Elahere
Biotech
ESMO: Genmab's ph. 3 win for Rina-S, fresh data on Merus prize
Genmab arrived in Spain with updated data from a pair of studies from the main prize of its Merus buyout, but the company had bigger news in store.
James Waldron
Oct 26, 2026 7:00am
Genmab ph. 2 data spur claim ADC ‘clearly superior’ to Elahere
Oct 5, 2026 4:14am
Genmab discards ADC from $1.8B ProfoundBio buy
Sep 16, 2025 10:33am
Genmab inks $1.8B ProfoundBio buyout for would-be Elahere rival
Apr 3, 2024 5:32am
